Quality of Life and Visual Function in Uveitis Patients

Learn more about:
Related Clinical Trial
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis Screening for NEI Clinical Studies Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications HAT in Eye Complications of Behcet’s Disease Golimumab for the Treatment of Refractory Behcet’s Uveitis Tocilizumab for the Treatment of Refractory Behcet’s Uveitis Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Quality of Life and Visual Function in Uveitis Patients Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Brief Title

Quality of Life and Visual Function in Uveitis Patients

Brief Summary

      The purpose of this study was to measure the quality of visual function and quality of daily
      living in patients with anterior, posterior, and panuveitis.

Detailed Description

      The National Eye Institute Visual Functioning Questionnaire, version August 2000 (NEI VFQ-25)
      and the Medical Outcomes Study (MOS) 36 Item Short Form Health Survey Instrument (SF-36)
      (RAND 36-Item Health Survey 1.0 Questionnaire) will be administered by a trained interviewer.
      Socio-demographic and clinical data will be collected for additional QOL parameter.

Study Type



Anterior Uveitis


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 2006

Completion Date

November 2006

Eligibility Criteria

        Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Subjects of either gender

          -  Age greater than or equal to 18 years of age

          -  Diagnosed with Uveitis




18 Years - 95 Years

Accepts Healthy Volunteers



C. Michael Samson, MD, 212-979-4251, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Study Sponsor

The New York Eye & Ear Infirmary

Study Sponsor

C. Michael Samson, MD, Principal Investigator, New York Eye and Ear Infirmary

Verification Date

December 2006